3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
8
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Head and Neck Neoplasms
2
Zollinger-Ellison Syndrome
1
Stomach Ulcer
1
Solid Tumours
1
Solid Tumor
1
Prostate Cancer Patients
1
Pharmacokinetics of MDV3100
1
Ovarian Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Inflammation
1
Hyperuricemia
1
Healthy Adult Participants
1
Gout
1
Esophagitis, Peptic
1
Colorectal Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
Arthritis
1
Advanced Solid Tumours
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Interventions
vandetanib
10
selpercatinib
5
cabozantinib
4
pralsetinib
3
yeast-CEA vaccine
1
rovalpituzumab tesirine
1
motesanib diphosphate
1
anlotinib
1
Sorafenib
1
Ranitidine
1
Omeprazole
1
Melphalan
1
Dexamethasone
1
Calcium Aluminosilicate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Medullary
×
Omeprazole
×
Clear all
NCT01539655
2017-05-02
Vandetanib
Sanofi
Phase 1
Completed
34 enrolled